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Abstract
This paper explores patients’ views and experiences of undergoing treatment-focused BRCA1 and BRCA2 genetic testing
(TFGT), either offered following triaging to clinical genetics (breast cancer) or as part of a mainstreamed care pathway in
oncology (ovarian cancer). Drawing on 26 in-depth interviews with patients with breast or ovarian cancer who had undergone
TFGT, this retrospective study examines patients’ views of genetic testing at this point in their care pathway, focusing on issues,
such as initial response to the offer of testing, motivations for undergoing testing, and views on care pathways. Patients were
amenable to the incorporation of TFGT at an early stage in their cancer care irrespective of (any) prior anticipation of having a
genetic test or family history. While patients were glad to have been offered TFGTas part of their care, some questioned the logic
of the test’s timing in relation to their cancer treatment. Crucially, patients appeared unable to disentangle the treatment role of
TFGT from its preventative function for self and other family members, suggesting that some may undergo TFGT to obtain
information for others rather than for self.
Keywords Treatment-focused genetic testing (TFGT) . BRCA1 and BRCA2 testing . Mainstreaming . Breast/ovarian cancer .
Clinical implementation . Patient experience
Introduction
The cumulative lifetime risk of developing breast cancer associ-
ated with a BRCA1 or BRCA2mutation, up to age 80, may be as
high as 72% and 69%, respectively (Kuchenbaecker et al. 2017),
and approximately 5–10%of newly diagnosed breast cancers are
thought to be attributable to aBRCA1 orBRCA2mutation (Claus
et al. 1996). For patients already diagnosed with breast cancer,
the risk of ipsilateral and contralateral cancers is considered sig-
nificantly higher among those with a germline BRCA pathogen-
ic variant (Haffty et al. 2002; Kuchenbaecker et al. 2017).
Cumulative lifetime risk of ovarian cancer associated with a
BRCA1 or BRCA2 mutation is estimated at 44% and 17%, re-
spectively (Kuchenbaecker et al. 2017), with 15.5% of patients
with epithelial ovarian cancer found to carry a mutation (Zhang
et al. 2011). Cancer predisposition genetic testing is offered to
patients with breast and/or ovarian cancers (Bdiagnostic^ testing)
as well as their unaffected relatives (Bpredictive^ testing). Such
tests have allowed for clinical implementation of risk-reducing
strategies, including enhanced screening using mammography
and or MRI (age-dependent) and risk-reducing surgery (mastec-
tomy, bilateral mastectomy, and/or salpingo-oophorectomy)
(National Institute for Health andCare Excellence [NICE] 2013).
Germline BRCA testing has been expanded from its pre-
dictive and diagnostic function to inform personalized cancer
treatment (NICE 2013); Scottish Intercollegiate Guidelines
Network 2013). This decision has been influenced by techno-
logical advances in gene sequencing, decreasing costs associ-
ated with genetic testing (Trainer et al. 2010) and the results of
clinical trials investigating the efficacy of poly(ADP-ribose)
polymerase (PARP) inhibitors targeted at BRCA pathogenic
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variants (George et al. 2017). This new treatment pathway is
referred to in a number of ways, including Btreatment-focused
genetic testing^ (hereafter TFGT) and Brapid genetic testing^
(NICE 2013). TFGT is offered to newly diagnosed breast and
ovarian cancer patients based upon considerations of age at
cancer diagnosis, tumor type, and family history. TFGT pro-
vides patients and healthcare providers with the information
needed to make strategic decisions with regard to definitive
surgical interventions and chemotherapeutic regimen while
also raising familial awareness of possible hereditary gene
mutations.
For breast cancer patients, trials suggest that BRCA
status can inform neo-adjuvant chemotherapy, with the use
of platinum-based therapy (Telli et al. 2015). When it
comes to surgical decision-making, knowledge of a
BRCA pathogenic variant can inform the extent of the
surgery and the appropriateness of radiotherapy (Weitzel
et al. 2003). Since approval by the Food and Drug
Administration (FDA), the European Medicines Agency
(EMA) (2014), NICE (2016), and the Scottish Medicines
Consortium (SMC) (2016), the PARP inhibitor olaparib
has been clinically implemented in patients with re-
lapsed, platinum-sensitive high-grade serous ovarian cancer
(Fong et al. 2010; Ledermann et al. 2014/Ledermann
et al. 2012) for Brelapsed and maintenance treatment
settings, respectively^ (Rafii et al. 2017). With BRCA
status providing prognostic information (Candido-dos-Reis
et al. 2015) and helping to predict sensitivity to cytotoxic
agents (Tan et al. 2008), ovarian cancer management now sees
patients Bbeing selected in clinical practice for biomarker-
directed therapy, based on presence of a BRCA1 or BRCA2
mutation^ (George et al. 2017). While PARP inhibitors are
now being used in clinical practice for ovarian cancer patients,
they have not yet been approved for treatment of breast cancer.
In reporting of the Phase 3 OlympiAD trial (ClinicalTrials.gov
NCT02000622), Robson et al. provide the latest evidence of
the Bpromising antitumor activity^ and progression-free sur-
vival associated with Olaparib when compared to standard
chemotherapy in breast cancer patients with metastatic disease
and a BRCA pathogenic variant (2017). Crucially, findings
indicate a need for further investigations, not least examining
the Brelative efficacy of olaparib and platinum-based
chemotherapy^ in breast cancer (Robson et al. 2017).
Mainstreaming Genetic Services
TFGT is symbolic of the shift towards mainstreaming of ge-
netics into cancer care promoted by the UK government
(Department of Health 2003; Davies 2017). Mainstreaming,
a process that involves the incorporation of genetic services
and expertise into standard medical care, represents a
Bparadigm shift^ in the way that healthcare is provided
(Rahman 2014). While there are different views as to how
mainstreaming should be realized in clinical practice
(Kentwell et al. 2017), the over-arching goal remains to offer
patients precision medicine and streamlined pathways of care
(House of Lords 2009), while also addressing capacity issues
faced by specialist genetics services (Slade et al. 2015). In
order to achieve universal mainstreamed pathways of care,
continued education of health care providers and members
of the public is required (Davies 2017; Rahman 2014). At
present, while some care pathways are working under a main-
stream model, triage and onward referral to genetic services
from specialist services continue. This provides an opportuni-
ty to compare the experiences of patients in a mainstreamed
care pathway with those whose care follows a standard model.
Patients’ Views of TFGT
While evidence exists as to patients’ experience of diagnostic
genetic testing, offered following completion of cancer treat-
ment (Meiser et al. 2008), there is limited evidence relating to
how patients view TFGT. Most of this research focuses upon
patients who have been offered TFGT during a research study
rather than as part of clinical care. Qualitative studies have
focused on the information needs and experiences of ovarian
cancer patients who underwent TFGTas eligibility criteria for
PARP inhibitor trials (Gleeson et al. 2013; Meiser et al.
2012a). Other studies have assessed patients’ information
preferences when offered TFGT; trialing streamlined methods
of information dissemination (Quinn et al. 2016), comparing
patients’ views of written information versus face-to-face
communication (Meiser et al. 2012b), and examining timing
preferences in relation to treatment decision-making (Wevers
et al. 2017). Studies, such as the Genetic Testing in Epithelial
Ovarian Cancer (GTEOC) (Plaskocinska et al. 2016), the
DNA-BONus study (Høberg-Vetti et al. 2016), and others
(Augestad et al. 2017; Meiser et al. 2016; Wevers et al.
2015/Wevers et al. 2016) have examined the acceptability
and feasibility of TFGTamong participants, in order to inform
future roll-out of TFGT in clinical practice. Key findings from
this research indicate that TFGT is commonly acceptable to
patients who appreciate the treatment implications of timely
testing (Gleeson et al. 2013; Meiser et al. 2012a/Meiser et al.
2012b; Wevers et al. 2017). There is little evidence that TFGT
is linked to adverse psychological effects (Høberg-Vetti et al.
2016;Wevers et al. 2015/Wevers et al. 2016), although studies
have recommended that care should be taken to ensure that
patients are treated with care and sensitivity when
implementing TFGT (Augestad et al. 2017; Shipman et al.
2017). In summary, research focusing on TFGT suggests that
the majority of patients do not find genetic testing to be an
additional stress. For those who do, there is an appreciation
that undergoing the test brings benefits that outweigh per-
ceived disadvantages (Meiser et al. 2012a).
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While numerous studies report the effects of undergoing
TFGT in research settings, few have examined patient re-
sponses to TFGT when it is offered as routine clinical care to
inform surgical interventions or types of adjuvant treatment. In
an early, prospective study evaluating the role of Bpre-
treatment^ genetic counseling and testing on surgical deci-
sion-making, Schwartz et al. (2005) found that this approach
was acceptable to patients, technically feasible, and informed
patients’ surgical management. Similarly, in a qualitative study
aimed at exploring the attitudes and experiences of women
offered TFGT as part of their treatment, Zilliacus et al.
(2012) found that TFGT was highly acceptable to patients
and there was general consensus that the testing should be
part of standard care. Finally, while Wevers et al. (2012) noted
that although some women in their study reported experienc-
ing additional distress linked to TFGT, the majority were glad
to have been offered the test and recognized its benefits.
While research suggests that patients recognize the benefits
of undergoing TFGT, care must be taken when extrapolating
from these studies because they involve women who have, in
the main, undergone TFGT in research protocols, and this may
impact the findings in two ways. First, participants may re-
ceive more or different attention and care in research studies
than in clinical care, and this may affect their responses.
Second, research studies, which include TFGT as an recruit-
ment tool or are specifically looking at the impact of TFGT,
may suffer from an ascertainment bias as they may recruit
participants who are more positive about TFGT from the out-
set, because they see study participation as a way of accessing
the study drug or gene testing for themselves or their family
(McDougall et al. 2016). The study reported circumvents
these potential biases by focusing on the experiences of breast
and ovarian cancer patients who underwent TFGT as part of
their routine clinical care.
Methods
Recruitment
Patients were recruited between January and November 2017
from a teaching hospital in the UK. Breast cancer patients
were identified by the clinical genetics department.
Eligibility criteria used to help identify possible participants
included the following: having been offered TFGT; being over
18 years of age; and, being a native English speaker.
Furthermore, patients with and without a family history (based
on Manchester Score) were approached, as were those with
and without an identified BRCA pathogenic variant. In total,
48 patients were sent an information pack which included an
Bexpression of interest^ form and pre-paid envelope. Twenty
six expression of interest forms were returned, three women
subsequently withdrew, due to being unwell, or were
subsequently unreachable, and, finally, five women indicated
they did not wish to participate.
Ovarian cancer patients received information packs from their
oncologist when they presented for check-ups andwere given the
opportunity to speak to SW in a separate clinic area if they
expressed an interest in participation. Eligibility criteria used to
help identify possible participants was the same aswith the breast
cancer patients; however, in addition, consultants were asked to
use professional discretion in introducing the study to individual
patients, so as to prevent women who were particularly upset
during consultation from being approached. In total, 41 ovarian
cancer patients were identified as possible participants. SW met
with and received expression of interest forms from 12 women.
Four women subsequentlywithdrew from the study, due to being
unwell, changing their minds, or not being contactable for inter-
view scheduling.
All participants underwent TFGT between 2013 and 2017,
either as part of a standard pathway involving triage and referral
to clinical genetics, in the case of breast cancer patients or, for
ovarian cancer patients, as part of their mainstream care in on-
cology (Fig. 1). Patients were selected so as to include those with
a pathogenic variant (hereafter BPV^), those in which no muta-
tion was detected (hereafter BNMD^), and those with a variant of
uncertain significance (hereafter BVUS^).
TFGT in Breast and Ovarian Cancer Pathways
Breast Cancer For patients with breast cancer, TFGT involved
initial triage in the breast clinic with onward referral to clinical
genetics for pre-test counseling and testing. The offer of test-
ing was contingent upon consideration of a combination of
factors, including the following: age at diagnosis, tumor type,
family history, and a discussion about appropriateness of re-
ferral at a multidisciplinary team meeting. TFGT was imple-
mented at three different points in the breast treatment path-
way, with some patients undergoing conservative surgery
(pathway 3) or neoadjuvant therapy (pathway 1) prior to learn-
ing of their BRCA result and others undergoing testing prior
to any form of cancer treatment (pathway 2) (Fig. 1).
Ovarian Cancer Ovarian cancer patients were consented and
tested for a pathogenic BRCA variant during their Bnew
patient^ medical oncology appointment (Fig. 1), following
surgery, this being as part of the mainstreamed pathway
established in 2012. During this consultation, pre-test infor-
mation was presented by the medical oncologist (Table 1) and
supplemented by written documentation from the local clini-
cal genetics team and the charity Target Ovarian Cancer.
While no immediate treatment decisions were contingent up-
on undergoing testing at this stage in the patients’ treatment,
genetic test results could inform future treatment options with
PARP inhibitors, while also providing family members with
knowledge of their own risk.
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Conducting Interviews
The University of Edinburgh Research Ethics Committee ap-
proved the study. SW conducted retrospective, semi-struc-
tured, face–face interviews with patients, using a broad topic
guide, focused on the following: diagnosis of cancer; family
history of cancer; expectations and experiences of genetic
testing; relevance of TFGT for self and family; views on
mainstreaming and/or the timing of testing in relation to can-
cer diagnosis and opinions about care. Interviews were digi-
tally recorded and lasted between 30 min and 2 h, with the
mean for breast cancer patients of 53 min and 57 min for
ovarian cancer patients, respectively. Audio files were tran-
scribed verbatim. In addition, SW kept field-notes of observa-
tions at the weekly breast multi-disciplinary teammeeting and
in the Bnew patient^ gynecology clinic. Memoing was used
through the fieldwork period in order to facilitate constant
reflection and analysis (Maxwell 2012). In order to safeguard
participants’ anonymity, pseudonyms were used in all written
documentations and are used in the reporting of data.
Data Analysis
We conducted a thematic analysis of our fieldwork materials
(transcripts and field-notes). In the first instance, SW and NH
spent time independently familiarizing themselves with the data,
listening to audio files, writing up individual patient narratives,
and reviewing transcripts (Pope et al. 2000). This process of
getting to know our data (Bradley et al. 2007) was the basis of
regular meetings between SW and NH, during which time
Key: MDM – multidisciplinary team meeting (Breast). 
        PV – pathogenic variant.  
        VUS – variant of uncertain significance. 
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Fig. 1 Patients’ pathways to
TFGT BRCA testing
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emerging ideas were discussed. Following this exploratory peri-
od, SW and NH independently coded all transcripts using
NVivo11 software (NVivo qualitative data analysis Software;
QSR International Pty Ltd. Version 11, 2015). This step allowed
for coding to begin, and, as with early reflections on our data,
regular meetings were held between SW and NH in order to
ensure consistency in coding and to address any discrepancies.
Once all of the data was coded, we started the process of creating
larger categories, thus drawing together our data thematically,
under three key themes: The offer of TFGT: Initial reactions;
Views of care pathways: timing of TFGT in relation to cancer
treatment; and, Participants’ motivations for undergoing TFGT:
constructing hope for prevention. Our approach to data analysis
was inductively and deductively determined (Maxwell 2012),
that is, we were influenced both by a priori research questions
(for example, seeking to understand patient experiences of un-
dergoing TFGT) as well as recognition of new insights (for ex-
ample, learning that the treatment function of TFGT is often
unacknowledged by patients). In conducting our research, we
were informed by an interpretive epistemology that is, concerned
with the multitude understandings of the world in which we each
find meaning. Further, we position the findings of this research
from the ontological standpoint that accepts the Balways partial,^
contingent nature of knowledge (Denzin 2009).
Findings/Results
The Sample
Twenty-six patients, 18with breast and eightwith ovarian cancer,
were interviewed (see Table 2).While we had initially planned to
interview 15 breast cancer patients and 15 ovarian cancer pa-
tients, we found that data saturation was reached after eight in-
terviews with patients with ovarian cancer and felt it suitable to
stop recruitment at that point. Of the 26 patients, 20 reported a
family history of cancer. Eight were found to carry a BRCA
pathogenic variant, 16 had NMD, and two were found to carry
a VUS. Despite the fact that BRCA testing is being promoted in
newly diagnosed breast cancer patients to inform their surgical
decision-making, 6/18 (33%) had already undergone conserva-
tive breast surgery (wide local excision), prior to receiving their
genetic test result (see Fig. 1, pathway 3). All the ovarian cancer
patients had been offered and had undergone genetic testing prior
to commencing adjuvant chemotherapy (Fig. 1, pathway 4).
Twenty-four participants had undergone TFGT between 6 and
12 months prior to the interviews, while the remaining two pa-
tients (1 breast cancer, 1 ovarian cancer) reported undergoing
TFGT roughly two years prior to participation in this study. We
tried but were unable to recruit patients who declined TFGT.
In most instances, cancer type did not appear to have an
impact on the experience of being offered TFGT, or percep-
tions as to the relevance of testing. Instances when differences
emerged between the accounts of these groups will be indicat-
ed in the succeeding analysis. Three main themes were iden-
tified in the data: The offer of TFGT: Initial reactions; Views of
care pathways: timing of TFGT in relation to cancer
treatment; and, Participants’ motivations for undergoing
TFGT: constructing hope for prevention.
The Offer of TFGT: Initial Reactions
Patients appeared to have different degrees of familiarity with the
concept of BRCA1 and BRCA2 genetic testing. A number of
Table 1 Introducing TFGT to
patients Breast unit Gynecology
Patients are usually triaged for TFGT during their first
surgical appointment following case discussion at
the weekly MDM. If considered by the team
(surgeons and breast oncologists) to meet testing
criteria, patients are offered a referral to clinical
genetics, by their surgeon, for pre-test counseling
and TFGT. The extent to which patients are in-
formed at this stage about the possible implications
of TFGT for surgery, adjuvant therapy, and the
family varies. For example, it was clear from ob-
servations of MDMs and clinician interviews that
while some felt comfortable to discuss various im-
plications of TFGT prior to the test, others were
more likely to take a staggered approach, that is,
only discussing surgical or adjuvant implications if
the patient is found to have a PVor VUS at which
point the patient is also referred back to clinical
genetics for further counseling and family cascad-
ing.
Patients are offered TFGT at the Bnew patient^ clinic.
The test is usually raised at the end of the
consultation and is presented as a straightforward
blood test that might help to explain why the
individual may have developed cancer. In these
appointments, there is little discussion of familial
implications, or treatment implications, associated
with a PVor VUS, although this varied slightly
between consultants. Instead, patients are assured
that if the test result comes back with a Bpositive^
result (PV, but also including VUS) that they will be
offered an appointment at clinical genetics in order
to discuss familial implications with a trained
genetic counselor. If the patient wishes to go ahead,
a specialist nurse takes the blood following the
consultation. Patients are given written information
by the consultant to take away with them.
Descriptions based upon observations of MDM, Bnew patient^ oncology clinic, and interviews with clinicians
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intervieweeswere aware of BRCA testing and had, either, sought
it out previously or were keen to raise it on this occasion with
their clinician. Just over half the women interviewed indicated
that, while they had heard of BRCA testing, they had never
considered it as relevant to themselves. Finally, only two women
stated that the technology was entirely new to them.
A small group described how the offer of TFGT had
allowed them to redress previous missed opportunities regard-
ing BRCA testing. These women were generally aware of
their family history of cancer and, in some cases, had visited
genetic services and requested a genetic test because of their
family history. Fran, for example, had previously requested
BRCA testing due to her family history of breast cancer only
to be refused, as she did not meet testing criteria. This expe-
rience of being refused predictive testing appeared to influ-
ence Fran’s eagerness in her response to the offer of TFGT:
I think to myself if they gave me the test when my sister
was diagnosed five years before I got my cancer, if they
gave me the test … I would never have had cancer
(Breast, PV).
Likewise, Lina described feeling regretful, and angry, when
TFGTwas raised. She had previously been offered predictive
BRCA testing, some two years prior to her diagnosis. She had
been keen to proceed at that time, but recalled being advised to
go away and think about it. She said, Blife took over … I
forgot all about it, two years went by. I started feeling not
well.^. When she was offered TFGT, her reaction was anger
at the missed opportunity to prevent cancer occurring:
I went to see oncologist and she said, BI think it’s a good
idea if we check for the BRCA gene at this point.^Which
mademe quite angry because I felt that had I had it done
when I’d asked for it two years before I could have
avoided all of this (Ovarian, PV).
In Lina’s case, the offer of TFGTwas received with complex,
and initially negative, emotions. She reflected that her re-
sponses had changed with the passing of time, and she de-
scribed herself as becoming a serious advocate of BRCA
testing:
But yeah, I have, I’ve told everybody that wants to listen
… to just go and have a check, you know, especially if
they’ve had cancer in the family, I said, BGo and have
the BRCA gene [test].^ Even my Callanetics teacher! So
I do put it out there. I mean it’s available, why not? Why
not? (Ovarian, PV).
While Fran, Lina, and a few others were aware of BRCA
testing for reasons linked to their family history of cancer,
others’ views of genetic testing appeared to have been
Table 2 Patients with breast cancer and with ovarian cancer
Patients with
breast cancer
Patients with
ovarian cancer
Age
Mean 48 64
Range 33–62 48–82
Marital status
Married/Partner 15 8
Single 2 –
Divorced 1 –
Children
Yes 14 8
Yes (adopted/non-biological) 1 –
No 3 –
Employment
Employed 10 –
Unemployed/not working 4 4
Retired 4 4
Time since cancer diagnosis
> 2 years 1 1
< 2 years 17 7
Timing of BRCA test
Prior to any treatment 5 –
During neo-adjuvant
chemotherapy
7 –
After wide local excision 6 –
After surgery (ovarian) – 8
BRCA result
Pathogenic variant 4 4
No known pathogenic mutation
found
12 4
VUS 2 –
Self-reported family history of cancera
None/none known, + past cancer
diagnosis
– 1
None/none known 3 2
≥ 1 first- and second-degree rela-
tive (BRCA and/or OVCA)
2 1
≥ 1 first-degree relatives (BRCA
and/or OVCA)
7 1
≥ 1 second-degree relatives
(BRCA and/or OVCA)
2 1
≥ 1 first-degree relatives (other
cancer)
4 2
Anticipated and/or previously asked for genetic test?
Yes 8 2
No 10 6
a For patients from families with extensive family history of different
cancers, only the closest relatives have been included. For example, if
someone has a grandmother with breast cancer, a grandfather with stom-
ach cancer, and an auntie with breast cancer, they will be listed under ≥ 1
second-degree relatives (BRCA and/or OVCA)
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influenced and informed by popular culture and the media.
For example, Loretta said she had not expected to be offered
a BRCA test as part of her care on the basis of her knowledge
of BRCA testing, which had been shaped by media discus-
sions of this technology:
I’d heard of it. I had very much the thought that it was in
families where you had you know, mum and aunties and
all your siblings and everyone gets breast cancer. … I
kind of thought you only hear of these families where
everyone has breast cancer or ovarian cancer and that’s
the gene. … I didn’t know anything about it in reality
(Breast, PV).
A few of the participants had watched a popular UK soap
opera that had a story line based upon BRCA testing and
described how this had informed their understanding of the
offer of testing and influenced their enthusiastic response:
When he mentioned that that—the first thing that came
into my EastEnders. And I said that to him. I said: I
know all about it. I’ve been watching EastEnders. So,
aye I didnae [mind]—I just said: aye. Go. Let’s go for it
(Bethany, Ovarian, NMD).
While family history of cancers and/or previous interactions
with genetic services appeared to form participants’ initial
response to the offer of TFGT, there were a few participants
for whom genetic testing seemed a completely novel proce-
dure. Maeve, had no prior awareness of genetic testing, but
said she was unperturbed by her oncologist’s offer of TFGT:
She said, Byou don’t have to have it,^ you know, she was
very, very nice about it and said, you know, BIt’s there,
the test’s there if you would like to have it.^ And I
thought it seemed silly not to have it. As I say, it wasn’t
anything that was going to be painful or intrusive as far
as I was concerned (Ovarian NMD).
What is clear from participants’ accounts of their initial
reaction to the offer of TFGT is that all were keen to undergo
testing independent of their cancer type and family history,
and irrespective of whether they had previously considered
testing before. Yet, while all participants described them-
selves, in hindsight, as feeling positive about the offer of test-
ing, their views about the timing of testing in relation to other
aspects of their treatment were more mixed.
Views of Care Pathways: Timing of TFGT in Relation
to Cancer Treatment
As noted previously (see Fig. 1), the patients in our study
underwent BRCA testing at various stages during their care.
Breast cancer patients on pathways 1 and 2 were offered, and
opted to undergo, TFGT prior to having surgical intervention
for their cancer. These patients commonly regarded this se-
quence of events as logical and timely. For example, Sarah
reflected on her experience of being offered the BRCA test
while undergoing neo-adjuvant chemotherapy (pathway 1):
I was pretty fed up when they suggested that it could be
the BRCA gene because I mean obviously it’s not a lot of
fun being diagnosed with breast cancer and going
through chemo and faffing round with everything and
then being told you could have the BRCA gene (Breast,
NMD).
Sarah continued, however, saying:
I mean it’s all very well pussyfooting round it. Say I’d
had a lumpectomy and then I had the BRCA gene test
and I tested positive then I might then have had to go on
and have further treatment [surgery]or chosen to go on
and have further treatment [surgery] which I could have
had done initially (Breast, NMD).
Here, Sarah conveys her appreciation of the logic of undergo-
ing TFGT during neo-adjuvant chemotherapy. As she points
out, if she had waited to undergo TFGT, she may well have
had to undergo multiple treatments (surgeries)—a treatment
pathway she clearly views as illogical. Georgina spoke of how
she was happy to go ahead with TFGT, when it was raised
prior to any form of treatment (pathway 2), seeing it as part of
the care available to her and, thus, something to engage with:
It was just better to keep on going, to be honest. I was
quite happy to do every single test underneath the sun
for me to be, to find out what was the best option for me
to be cancer-free, and what was the quickest way—well,
as much as you can go with the NHS to get to that. And
once they had suggested the genetic treatment then …
again it was just, yeah, I wasn’t anxious at all (Breast,
NMD).
Women who were tested during their neo-adjuvant chemo-
therapy (pathway 1) or prior to any surgery (pathway 2) com-
monly regarded the introduction of TFGTas an important and
easy step in their care. As hinted at in Sarah’s example, it
could be experienced in the short term as an added stress,
but this was balanced against an appreciation of the purpose
of testing, namely, to determine the most appropriate or logical
treatment package for the individual.
Ovarian cancer patients (pathway 4), in contrast, were of-
fered BRCA testing at the Bnew patient^ oncology consulta-
tion following their ovarian surgery and prior to commencing
adjuvant chemotherapy. Similar to the breast cancer patients
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on pathways 1 and 2, all of these patients viewed the timing of
the test positively, as Maureen indicated:
No I didnae sort of think, oh my God no, something else,
you know. I was quite willing, you know. I don’t know, I
think I just, to me it’s just all, it was just partly what I
needed to do, kind of thing, you know (Ovarian, PV).
Not all patients, however, were uniformly positive about
the timing of TFGT in relation to their treatment. Unlike path-
ways 1 and 2, which allowed for the test result to be known
prior to any breast surgery, pathway 3 saw breast cancer pa-
tients undergoing conservative surgery before their BRCA test
result had been returned. Proceeding with conservative sur-
gery prior to receiving the BRCA result, only to undergo more
radical surgery at a later date, if indicated by TFGT, was
regarded by these women as illogical. Indeed, most of these
patients said they felt confused by the sequence of events,
particularly those who received a positive mutation result after
having already undergone conservative breast surgery. While
they were pleased to have had their cancer dealt with speedily,
this group was left wondering about the logic of enduring
multiple surgeries, as Loretta, who had undergone subsequent
surgeries, reflected:
I met with the consultant on the Monday and he said
BI’ve got a cancellation onWednesday. You can come on
Wednesday for your operation.^ So I had a lumpectomy
and my lymph nodes removed. So once that was kind of
all done … [he] took me forward for genetic testing.
Obviously you kind of think if I had, if somehow the test
results could come back instantly, you know then obvi-
ously I would have gone for a double mastectomy
straight away. And it’s interesting because when I was
diagnosed with cancer and [surgeon] said Byou can
come in on Wednesday and have you know, and have
the lumpectomy ,^ my first response was Bcan I not have
a mastectomy?^ So that was my—there was no thought
there at all. That just came out of my mouth. And he just
said Bthere is absolutely no need for you to have a
mastectomy .^ He’s like Bthe lumpectomy it’s all you
need. It’s a very small cancer. That’s far too ridic-—,
he’s like, Bthat’s a ridiculous response^ (laughter). In
the nicest possible way. But you know there was like
we don’t need to go down that road. So obviously part
of me thinks ah why didn’t I just push and say, I wanted a
mastectomy, because that was obviously my gut reaction
(Breast, PV).
On a more general level, interviewees had differing views
of the significance of TFGT in relation to their experience of
cancer diagnosis and treatment. For some, TFGT featured
prominently, while for others it was only a minor part of their
story. In all instances, however, participants felt that TFGT
should be made available to others in similar situations.
Alice reflected on the impact that TFGT had had on her ex-
perience of cancer. For her and her family, the test amounted
to a significant moment in her treatment, something that stood
out from the multitude of other tests she was undergoing at the
time:
It was quite an important one … Some things stay in
your memory and some things go and people have to
remind you of them … I can still remember that day, I
can still visualize my husband parking the car, going in,
sitting at the table, I can still visualize the room, the
chair that I sat on to have the bloods taken, it was a
really important part of the journey (Breast, NMD).
For others, TFGT was not a particularly noteworthy event;
receiving a diagnosis of cancer, and working through the
resulting emotions, meant that genetic testing faded into the
background. As Florence said: Bit definitely wasn’t a big upset
or anything like that, it was just another thing that was going
on at that time.^ Florence went on to say that she Bcould
probably easily miss it out if I was telling someone the story
… it was totally in the shadow of everything else^ (Breast,
NMD).
Whether TFGT featured prominently in interviewees’ ac-
counts of their care or not, it was nevertheless the case that,
with the exception of some patients in pathway 3, most inter-
viewees approved of the way TFGT had been incorporated
into their cancer care. When considering interviewees’ posi-
tive response to TFGT, this appeared to have been shaped by
their understanding of its relevance, for themselves and family
members. Indeed, as the next section indicates, interviewees’
motivations for consenting to TFGTwere primarily fueled by
their appreciation of the predictive utility of BRCA testing.
Participants’ Motivations for Undergoing TFGT:
Constructing Hope for Prevention
As noted in the BIntroduction^ section, the purpose of TFGT
is to inform decision-making about the treatment of cancer. In
the case of breast cancer patients, this relates to, both, neo-
adjuvant treatment and surgical options, and in the case of
ovarian cancer patients, it relates to chemotherapy regime.
While there are clear treatment implications related to a pa-
tient’s BRCA status, our findings revealed that appreciation of
the individual treatment function of TFGT was rarely
expressed by breast cancer patients and not at all by ovarian
cancer patients. Indeed, for the majority of patients in this
study, the main motivation to undergo TFGT was to prevent
future cancers in self and others, rather than to treat their own
cancer.
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Breast cancer patients frequently talked about the
need to prevent future cancers occurring, and described
their uptake of TFGT as motivated by a more general
desire to stay alive to parent their children.
So my main motivation was my children, and really for
two reasons. One is I need to survive as long as possible,
because at the time [they] were four months, and seven
years. And I absolutely want to see them as teenagers.
That’s kind of my life goal, I think my main goal in my
life is to just see them when they’re, I want both of them
to be taller thanme one day. And so I wanted to know if I
had to have any more operations to minimize the risk
(Pia, Breast, VUS).
For other patients, the motivations to undergo TFGT
reflected both a concern to prevent cancer developing in self
and determine others’ risks:
If it had been gene positive, strongly gene positive com-
ing up, then I would have probably been more pushy
towards trying to get mastectomies etc. at that stage or
at least discuss it further with my breast surgeon as an
option as opposed to a lumpectomy so that was where I
was coming from. But I’m also aware that while I don’t
have children I’ve got two sisters and I’ve got several
nieces and nephews and things so it was to really start
the creation of a sort of family tree (Jenny, Breast,
NMD).
Finally, there were patients who appeared to be primar-
ily driven to undergo TFGT by their desire to prevent
family members from developing cancer by providing
them with empowering information. As Alice reflected:
The whole genetic thing as well it was important for me
to know, to have that, to be able to sleep at night know-
ing right I’ve done that part of it and I’ve done that part
of it for my girls. So now my daughters get tested, they’ll
get mammograms at 40 rather than 50 so they bring it
forward 10 years (Breast, NMD).
Indeed, the need to act responsibly towards family
members was a commonly expressed across both patient
groups, with ovarian cancer patients exclusively framing
their sole motivation to undergo TFGT as underpinned
by the need to generate information for their family:
I was more concerned that they were carrying it than
whether I had it or not, because, well, I wasn’t as young
[laughing] as I used to be, and you know, I’d had, I’d got
the cancer so, you know… That was, that was my main
reason was to see if they were all right, and if they
needed to be tested (Maeve, Ovarian, NMD).
I would have said, given that I was 67 it wasn’t partic-
ularly because of me it was because of my children, and
that… yeah, I decided to have it (Sylvia, Ovarian, PV).
The hope that BRCA testing would garner information that
could be mobilized for prevention, coupled with a sense of
familial responsibility, featured heavily in all the participants’
accounts. Thus, it was difficult to find patients clearly express-
ing an understanding of their BRCA test as being treatment-
focused, instead it appeared that most interviewees regarded
its main role as preventing future cancers in self and others.
Discussion
Our findings indicate that, irrespective of family history
of cancer, cancer type, and care pathway, women were
overwhelmingly receptive to TFGT. Furthermore, none
of the participants framed TFGT as being too much to
take on so soon after their diagnosis. These findings can
be examined in relation to the literature concerning the
psychological impact of BRCA testing on individuals
and confirm that, when conducted with care and with
sensitivity to individual needs, BRCA testing is regarded
as acceptable (Braithwaite et al. 2004; Meiser et al. 2008;
Meiser et al. 2012a; Schlich-Bakker et al. 2006; Wevers
et al. 2016; Zilliacus et al. 2012). While the hypothetical
idea of BRCA testing post-diagnosis of cancer (Ardern-
Jones et al. 2005) or specifically treatment-focused testing
(Augestad et al. 2017; Shipman et al. 2017) has been
found to raise concerns about, or actual feelings of,
heightened emotional distress at a time of being diag-
nosed with a life-threatening disease, these reservations
were not expressed in this study. For some of our partic-
ipants, TFGT was an attractive option as they already
knew about the test and, in a small number of cases,
had previously sought it out. Those who had been unable
to access testing prior to their cancer diagnosis expressed
regret at a missed opportunity—a finding similarly noted
in Vadaparampil et al. (2008) in their qualitative study of
newly diagnosed breast cancer patients’ views on pre-test
genetic counseling. Others’ familiarity with BRCA was
shaped by media accounts, and there was evidence of
the BAngelina Jolie Effect^ (see Evans et al. 2014)
informing their (positive) view of the offer of testing.
This finding is congruent with what Crabb and
LeCouteur (2006) describe as the normalizing effect of
popular media representations of (breast) cancer preven-
tion. Even participants for whom TFGT was an entirely
novel procedure appeared to trust in the technology,
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viewing it as beneficial—as something they should en-
gage with.
In addition to the positive manner in which participants
received the offer of TFGT, the majority felt that the technol-
ogy was implemented at the right time in their care pathway.
Breast cancer patients who awaited their BRCA result prior to
starting treatment, or who were undergoing neo-adjuvant che-
motherapy at the time of testing, appreciated the logic of the
timing of TFGT, specifically in relation to shaping surgical
decisions, a finding also noted by Schwartz et al. (2005).
Meiser et al. (2012b) report a similar finding in their study
of patient preferences for information around breast cancer
diagnosis and TFGT. They found that the majority of patients
wanted to know of their BRCA status prior to any surgical
intervention to ensure that both cancer and risky breast tissue
was removed Bin one go^ (2012). A similar sentiment was
echoed by all the breast cancer patients in this study. Indeed,
even the patients with a pathogenic variant who underwent
conservative surgery prior to learning of their BRCA status,
appreciated the impetus to eradicate the cancer, while simul-
taneously expressing frustration at the illogical sequence of
events they had experienced. Other studies examining role
and optimum timing of BRCA testing for surgical decision-
making have similarly noted discrepancies in the timing of the
test and the impact of this on women’s definitive treatment
(Stolier et al. 2004; Weitzel et al. 2003). These studies have
argued that, ideally, rapid BRCA should be actioned, if possi-
ble, to allow women to make best use of simultaneous risk-
reducing and therapeutic surgery.
Patients with ovarian cancer were all offered TFGT during
their initial oncology consultation, following their surgery,
and we found that this timing was acceptable to all. Unlike
Shipman et al.’s (2017) study, in which staff observed that
undergoing TFGT caused some women additional distress at
a time when diagnosis of ovarian cancer had already drained
much of their emotional resources, our interviewees reported
feeling that BRCA testing was important and demanded little
of them. There are a few possible reasons for these differences.
First, the observed differences may be due to the fact that
Shipman et al. focused on staff perceptions of patients’ expe-
riences, while we focused on patient experiences directly.
Second, the patients in our study had had time to come to
terms with their diagnosis, which was usually given by their
surgeon prior to meeting with their oncologist. By the time
they were at their initial oncology consultation, it seems that
they were focused on the question of Bwhat to do now?^ and
open to learn more about the options available to them, in-
cluding TFGT. Third, while patients in Shipman et al. went
through a number of steps to BRCA testing, our patients were
consented in one visit, following a brief account of BRCA
testing from their oncologist. This may have resulted in them
regarding the test as less important and therefore as less anx-
iety provoking than the patients described by the staff in
Shipman et al.’s study, who were informed of both the clinical
and familial implications of testing by research genetic coun-
selors prior to TFGT. It must be noted, however, that the breast
cancer patients in our study also received information about
personal and familial implications of the test in a clinical ge-
netics appointment before undergoing TFGT, but did not ap-
pear to respond differently to the ovarian cancer patients we
interviewed; suggesting that the timing and extent of informa-
tion giving in TFGT may not be a contributory factor leading
to distress in this patient group as Shipman et al. suggest.
Indeed, our findings suggest that participants’ responses to
TFGT might well have been informed by their perception of
the test’s utility. We observed in participants’ accounts a com-
mon lack of appreciation of the treatment function of TFGT,
with breast cancer patients rarely understanding the treatment
role of the test (Vadaparampil et al. 2008) and ovarian cancer
patients appearing to be completely unaware of this. Thus,
when it came to the issue of treatment—the element of
TFGT that distinguishes it from other forms of germline
BRCA testing—there was a general lack of awareness and
understanding in participants’ reflections. Not only was im-
mediate treatment of current cancer rarely expressed as a mo-
tivator for undergoing TFGT, but in the minority of instances
where treatment was understood, it was ambiguously de-
scribed, and almost indistinguishable from individual’s hopes
for prevention. Indeed, patients’ receptiveness to TFGT ap-
peared shaped by their understanding of the test’s preventative
utility; most regarded BRCA testing as a means to
Bweaponize^ themselves and their families against future
pathological threats—cancer. Thus, these results suggest they
conceptualized TFGT as a predictive tool and testing as a
familial rather than a personal matter.
It is possible that the lack of recognition regarding the
treatment potential of TFGT among participants was due, in
part, to the ways in which this technology is mobilized in the
clinic. In the case of breast cancer, the treatment or curative
response is commonly combined with preventive measures in
the form of bilateral mastectomy (Chiba et al. 2016). Thus, it
is not surprising that patients might conflate treatment and
prevention in their accounts. When it comes to ovarian cancer
patients, the treatment role of TFGT is more abstract, as the
use of PARP inhibitors for treatment and maintenance only
comes in to effect at a later stage, when the patient is relapsed
and platinum-sensitive (Alsop et al. 2012). Put simply, the
main therapeutic decision contingent upon the genetic test
(PARP inhibitor treatment) would not become relevant until
relapse. Thus, testing soon after diagnosis for treatment pur-
poses temporally distances the act from its function. With that
said, testing at point of diagnosis does ensure that patients do
not miss the opportunity to have testing, and may save lives in
the wider family group as it allows relatives to access risk
reducing surgery earlier. With only one of the ovarian cancer
patients mentioning being treated with Olaparib at the time of
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this study (a woman who, it must be noted, did not appear to
understand why she was on PARPi treatment), it is perhaps
unsurprising that these women did not consider that BRCA
testing had been undertaken for treatment purposes as it had
not resulted in different treatment in their experience.
Although these accounts rarely engaged with the treatment
role of TFGT, patients appeared highly motivated to undergo
BRCA testing for reasons documented in previous research on
predictive and diagnostic testing, namely: to provide informa-
tion for their family (Douglas et al. 2009; Hallowell 1999;
Hallowell et al. 2003; Shipman et al. 2017), to fulfill the gen-
dered role of caring (D’Agincourt-Canning 2001; Rowley
2007), and to ascertain future cancer risks for themselves
(Hallowell et al. 2004; Lodder et al. 1999). That these women
wished to provide their families with genetic information is
not surprising, given that the prognosis for ovarian cancer is
often poor (Shipman et al. 2017). Indeed, many of the patients
with ovarian cancer in our study regarded themselves as un-
likely to benefit personally from preventative steps, but
underwent testing for their family’s sake. In this way, our
interviewees justified their decision to engage with TFGT
not as autonomous individuals but as related and interconnect-
ed persons (Hallowell 1999, Hallowell et al. 2003; Rose
2007). As TFGT becomes more widespread in clinical prac-
tice it is possible that lay understandings of the treatment role
of germline testing will change and patients’ motivations to
undergo this form of testing will become more individualistic.
Finally, we suggest that a possible explanation for why the
majority of participants in this study appeared to be so positive
about the integration of TFGT into their cancer care might be
found in what Therond refers to as the Bnarrative paradox of
the BRCA gene^ (2016: 46). In her study of mainstreamed
BRCA testing for ovarian cancer, Therond observed that pa-
tients paradoxically describe BRCA pathogenic variants as
both the cause of their suffering and Bobjects of hope^
(2016: 46). This paradox is also present in our interviewees’
accounts, which similarly describe BRCA pathogenic variants
as causing cancer and suffering, while also alerting them to,
and empowering them (and others) against, future cancer
risks.
Strengths and Limitations
This study contributes to understandings of patients’ views
and experiences of TFGT, an area which NICE indicated re-
quires investigation (NICE 2013). Further, the study adds to a
paucity of evidence comparing the experiences of TFGT
among patients with and without a strong family history of
cancer and demonstrated that the presence of a family history
of disease has little impact on patients’ views of TFGT. The
study is one of the first to compare the experiences of patients
undergoing TFGTas part of a standard versus a mainstreamed
pathway, indicating that perceptions of the acceptability of
TFGT were not influenced by whether testing was offered in
specialist or mainstream services.
With regard to its limitations, this study has an overall re-
cruitment rate of 29% (37.5% breast cancer patients, 19.5%
ovarian cancer patients). We are aware that the different ap-
proaches to recruitment of breast cancer patients (mail-out)
and ovarian cancer patients (recruitment through oncologists)
might have impacted on recruitment rates. Relying on clinicians
to recruit patients directly is not an infallible recruitment meth-
od, not least because it depends on them remembering to raise
the research with their patients. While the direct approach by
clinicians proved the only ethical and practical means for
recruiting ovarian cancer patients in this study, it means that
we do not have data on the actual number of patients
approached, which in turn may mean that our recruitment rates
may have exceeded those above. Despite the best of intentions,
we were unable to recruit those who had declined TFGT.
Anecdotal reports from clinicians involved in the study suggest
that nearly all patients approached accept and proceed to test-
ing, and no decliners were identified for recruitment.
As this study was retrospective in design, we do not know
to what extent interviewees’ account were tainted by hind-
sight. Finally, all participants were recruited from the same
hospital, albeit through different pathways and at different
clinics, and received information (written or face-to-face)
about TFGT designed by the same clinical genetics team. It
is unclear how orwhether this influenced our findings. Indeed,
a wide variety of staff were involved in participants’ care and,
given that participants’ views recapitulate those of other stud-
ies with regard to their experiences of TFGT, it is unlikely that
sampling from a single site is problematic.
Research Recommendations
To the best of our knowledge, we only recruited one patient
who recalled taking PARP inhibitors, future research might
engage with patients who have undergone PARPi therapy, in
order to determine whether this alters their understanding of the
treatment role of the test. Finally, future research employing a
prospective design, including quantitative methods of data col-
lection, might provide greater insight into changes in percep-
tions and emotional responses to TFGT offered in the clinical
setting and, if multi-sited, may also maximize the chances of
recruiting patients who decline the offer of testing.
Clinical Implications
This study demonstrates that patients with breast or ovarian
cancer regard TFGT positively, irrespectively of whether it is
offered in mainstream care by a non-genetics specialist or fol-
lowing referral to a specialist genetics clinic. This suggests that
mainstreamed genetic testing is acceptable from a patient’s
point of view when it is implemented in a supportive manner
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by trained clinicians. Given that patients often framed their
motivations to undergo testing in relation to caring for their
family, it is recommended that clinicians should emphasize
the individual, treatment focused aspects of the test to patients,
while nevertheless remaining mindful of, and attending to, the
potential informed consent issues pertaining to testing for fam-
ily members, and the ways in which familial relations work to
shape individual decision-making about genetic testing.
This research has demonstrated that patients are comfort-
able undergoing TFGT in oncology and, thus, provides evi-
dence to support the future mainstreaming of clinical genetics
expertise into non-genetic specialties. Through the develop-
ment of pathways that incorporate genetic services into stan-
dard care, the mainstreaming of BRCA testing might help to
address some of the capacity issues currently experienced by
genetic services in the UK and elsewhere while also providing
care that is acceptable to patients.
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